Skip to main content
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 2003 Sep;111(12):1550–1558. doi: 10.1289/ehp.5870

The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies.

Jun Kanno 1, Lesley Onyon 1, Shyamal Peddada 1, John Ashby 1, Elard Jacob 1, William Owens 1
PMCID: PMC1241660  PMID: 12948897

Abstract

The Organisation for Economic Co-operation and Development has completed phase 2 of an international validation program for the rodent uterotrophic bioassay. This portion of phase 2 assessed the reproducibility of the assay with a battery of positive and negative test substances. Positive agonists of the estrogen receptor included the potent reference estrogen 17-ethinyl estradiol (EE), and the weak estrogen agonists bisphenol A, genistein, methoxychlor, nonylphenol, and o,p -DDT. The negative test substance or nonagonist was n-dibutylphthalate. The test substances were coded, and prescribed doses of each test substance were administered in 16 laboratories. Two versions of the uterotrophic assay, the intact immature and the adult ovariectomized female rat, were tested and compared using four standardized protocols covering both sc and po administration. Assay reproducibility was compared using a) EE doses identical to those used in phase 1 and in parallel dose-response studies, b) single doses of the weak agonists identical to one of five doses from the dose-response studies, and c) a single dose of the negative test substance. The results were reproducible and in agreement both within individual laboratories and across the participating laboratories for the same test substance and protocol. The few exceptions are examined in detail. The reproducibility was achieved despite a variety of different experimental conditions (e.g., variations in animal strain, diet, housing protocol, bedding, vehicle, animal age). In conclusion, both versions of the uterotrophic bioassay and all protocols appear robust, reproducible, and transferable across laboratories and able to detect weak estrogen agonists. These results will be submitted along with other data for independent peer review to provide support for the validation of the uterotrophic bioassay.

Full Text

The Full Text of this article is available as a PDF (150.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blair R. M., Fang H., Branham W. S., Hass B. S., Dial S. L., Moland C. L., Tong W., Shi L., Perkins R., Sheehan D. M. The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. Toxicol Sci. 2000 Mar;54(1):138–153. doi: 10.1093/toxsci/54.1.138. [DOI] [PubMed] [Google Scholar]
  2. Christian M. S., Hoberman A. M., Bachmann S., Hellwig J. Variability in the uterotrophic response assay (an in vivo estrogenic response assay) in untreated control and positive control (DES-DP, 2.5 microG/kg, bid) Wistar and Sprague-Dawley rats. Drug Chem Toxicol. 1998;21 (Suppl 1):51–100. doi: 10.3109/01480549809007404. [DOI] [PubMed] [Google Scholar]
  3. Ema M., Miyawaki E. Adverse effects on development of the reproductive system in male offspring of rats given monobutyl phthalate, a metabolite of dibutyl phthalate, during late pregnancy. Reprod Toxicol. 2001 Mar-Apr;15(2):189–194. doi: 10.1016/s0890-6238(01)00111-3. [DOI] [PubMed] [Google Scholar]
  4. Ema M., Miyawaki E., Kawashima K. Critical period for adverse effects on development of reproductive system in male offspring of rats given di-n-butyl phthalate during late pregnancy. Toxicol Lett. 2000 Jan 5;111(3):271–278. doi: 10.1016/s0378-4274(99)00192-7. [DOI] [PubMed] [Google Scholar]
  5. Kanno J., Onyon L., Haseman J., Fenner-Crisp P., Ashby J., Owens W., Organisation for Economic Co-operation and Development The OECD program to validate the rat uterotrophic bioassay to screen compounds for in vivo estrogenic responses: phase 1. Environ Health Perspect. 2001 Aug;109(8):785–794. doi: 10.1289/ehp.01109785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kanno Jun, Onyon Lesley, Peddada Shyamal, Ashby John, Jacob Elard, Owens William. The OECD program to validate the rat uterotrophic bioassay. Phase 2: dose-response studies. Environ Health Perspect. 2003 Sep;111(12):1530–1549. doi: 10.1289/ehp.5780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Mylchreest E., Cattley R. C., Foster P. M. Male reproductive tract malformations in rats following gestational and lactational exposure to Di(n-butyl) phthalate: an antiandrogenic mechanism? Toxicol Sci. 1998 May;43(1):47–60. doi: 10.1006/toxs.1998.2436. [DOI] [PubMed] [Google Scholar]
  8. Mylchreest E., Sar M., Cattley R. C., Foster P. M. Disruption of androgen-regulated male reproductive development by di(n-butyl) phthalate during late gestation in rats is different from flutamide. Toxicol Appl Pharmacol. 1999 Apr 15;156(2):81–95. doi: 10.1006/taap.1999.8643. [DOI] [PubMed] [Google Scholar]
  9. Shultz V. D., Phillips S., Sar M., Foster P. M., Gaido K. W. Altered gene profiles in fetal rat testes after in utero exposure to di(n-butyl) phthalate. Toxicol Sci. 2001 Dec;64(2):233–242. doi: 10.1093/toxsci/64.2.233. [DOI] [PubMed] [Google Scholar]
  10. Zacharewski T. R., Meek M. D., Clemons J. H., Wu Z. F., Fielden M. R., Matthews J. B. Examination of the in vitro and in vivo estrogenic activities of eight commercial phthalate esters. Toxicol Sci. 1998 Dec;46(2):282–293. doi: 10.1006/toxs.1998.2505. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES